Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/4863
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCOSTA, Daniel L. C.-
dc.contributor.authorDINIZ, Juliana B.-
dc.contributor.authorJOAQUIM, Marines-
dc.contributor.authorBORCATO, Sonia R.-
dc.contributor.authorVALERIO, Carolina-
dc.contributor.authorMIGUEL, Euripedes C.-
dc.contributor.authorSHAVITT, Roseli G.-
dc.date.accessioned2014-02-17T20:55:48Z-
dc.date.available2014-02-17T20:55:48Z-
dc.date.issued2012-
dc.identifier.citationBIOLOGICAL PSYCHIATRY, v.71, n.8, suppl.S, p.56S-57S, 2012-
dc.identifier.issn0006-3223-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/4863-
dc.description.abstractBackground: Delayed onset of response to serotonin reuptake inhibitors represents a challenge in obsessive-compulsive disorder (OCD) treatment. In depression, absence of improvement in the first weeks has been raised as a motive to switch antidepressants before full non-response is observed. We aimed to investigate if early improvement is a predictor of OCD outcome after 12 weeks. Methods: Participants (n=150) were admitted to a specialized OCD outpatient program. Inclusion criteria: age 18-65, DSM-IV diagnosis of OCD, minimum baseline Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score of 16, absence of previous pharmacological treatment for OCD. Fluoxetine was used up to 80mg/day. Systematic assessments were taken at baseline, weeks 4 and 12. Non-improvement at 4-weeks was defined as no reduction of baseline Y-BOCS scores. Response at 12 weeks was defined as 35% or greater decrease in baseline Y-BOC score. Spearman correlation, linear regression and chi-square test were performed to test the relationship between improvement at 4-weeks and the 12-weeks outcome. Results: Mean Y-BOCS scores(SD) at baseline, 4 and 12 weeks were, respectively: 27.3(5.4), 22.8(6.9) and 20.8(8.3). Correlation coefficient for 4-weeks improvement and 12-weeks outcome was 0.43(p=0.01). Linear regression analysis showed no-effect of the covariates on 12-weeks outcome and confirmed the relationship between improvement at 4-weeks and outcome at 12 weeks (β coef= 0.44, p< 0.01). Only five (11.9%) non-responders at 4-weeks were responders at 12-weeks (Pearson Chi-Square= 9.1, p= 0.003). Conclusions: Early improvement predicted 12-weeks outcome of OCD, which may have a role in early decision-making in OCD treatment.-
dc.language.isoeng-
dc.publisherELSEVIER SCIENCE INC-
dc.relation.ispartofBiological Psychiatry-
dc.rightsrestrictedAccess-
dc.subjectearly improvement-
dc.subjecttreatment response-
dc.subjectobsessive-compulsive disorder-
dc.subjectserotonin reuptake inhibitors-
dc.subjectpredictors-
dc.titleCan Early Improvement be an Indicator of Treatment Response at Twelve Weeks in Obsessive Compulsive Disorder? Implications for Early-Treatment Decision-Making-
dc.typeconferenceObject-
dc.rights.holderCopyright ELSEVIER SCIENCE INC-
dc.description.conferencedateMAY 03-05, 2012-
dc.description.conferencelocalPhiladelphia - PA, USA-
dc.description.conferencename67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry-
dc.subject.wosNeurosciences-
dc.subject.wosPsychiatry-
dc.type.categorymeeting abstract-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage56S-
hcfmusp.description.endpage57S-
hcfmusp.description.issue8-
hcfmusp.description.issuesuppl S-
hcfmusp.description.volume71-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000302466000181-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
dc.description.indexMEDLINE-
Appears in Collections:

Comunicações em Eventos - FM/MPS
Departamento de Psiquiatria - FM/MPS

Comunicações em Eventos - HC/IPq
Instituto de Psiquiatria - HC/IPq

Comunicações em Eventos - LIM/21
LIM/21 - Laboratório de Neuroimagem em Psiquiatria


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.